Covis pharma

AstraZeneca Sells COPD Drug Rights to Covis

AstraZeneca has agreed to transfer its global rights to two drugs for treating patients with chronic obstructive pulmonary disease (COPD) to Switzerland’s Covis Pharma for $270 million. The transaction is expected to close in the fourth quarter of 2021.

News

Covis Buys US Biotech Amag Pharmaceuticals

Specialty pharma company Covis has agreed to buy US-based Amag Pharmaceuticals, boosting its portfolio of therapies for life-threatening conditions and chronic illnesses.

News

AstraZeneca Sells Synagis Rights to Sobi

Top-Feature

Evonik (Darmstadt)

Unlocking the Value of Plastic Waste with Pyrolysis Oil

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

JULABO GmbH

When Every Temperature Change Determines the Process

INOSIM GmbH

Predictive Simulation in Pharma Production

Free Virtual Event

CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

AstraZeneca